ENDLOS-TURBO CALL - NOVAVAX Share Price

Certificat

DE000DDZ2AW1

Delayed Deutsche Boerse AG 20:35:10 09/11/2023 GMT
0.26 EUR -.--% Intraday chart for ENDLOS-TURBO CALL - NOVAVAX
1 month-16.13%
3 months-10.34%

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying NOVAVAX, INC.
Issuer DZ BANK
WKN DDZ2AW
ISINDE000DDZ2AW1
Date issued 28/02/2023
Strike 5.614 $
Maturity Unlimited
Parity 10 : 1
Emission price 0.52
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.66
Lowest since issue 0.22

Company Profile

Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Sector
-
More about the company

Ratings for Novavax, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Consensus: Novavax, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
15.7 USD
Average target price
19.75 USD
Spread / Average Target
+25.80%
Consensus